News Headlines

  1. Prestige Biopharma And Biosidus Enter Exclusive License Agreement For Tuznue® Commercialization In Latin America 11/26/2025

    Prestige Biopharma, a biopharmaceutical company specializing in antibody therapeutics, today announced an exclusive license and supply agreement with Biosidus, a biotechnology company headquartered in Buenos Aires, Argentina, with decades of experience in biosimilar development and commercialization, for the commercialization of Tuznue® (trastuzumab) across Latin American markets, including Argentina, Mexico, Bolivia, and Paraguay.

  2. Zydus And RK Pharma Enter Into An Exclusive Licensing And Commercialization Agreement For A Novel 505(b)(2) Product Of Supportive Oncology Treatment For The USA Market 11/26/2025

    Zydus Lifesciences Ltd. (including its subsidiaries and affiliates), a global innovation-driven healthcare company, today announced that it has entered into an exclusive licensing and commercialization agreement with RK Pharma Inc of the US for a novel sterile injectable 505(b)(2) oncology supportive care product for the US market.

  3. Algorithm And Batterjee Pharma Sign Strategic Partnership Agreement To Localize Key Pharmaceuticals In KSA 11/25/2025

    Algorithm, a pioneering regional pharmaceutical manufacturer has announced the signing of a strategic partnership agreement with Batterjee Pharma, a leading Saudi pharmaceutical company, becoming the first Lebanese company to localize its portfolio in the Kingdom.

  4. Scaleready Grant To Fuel Development Of Innovative Cancer Treatments At The Ottawa Hospital's Biotherapeutics Manufacturing Centre 11/25/2025

    ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, announced today that the Biotherapeutics Manufacturing Centre (BMC) at The Ottawa Hospital’s Research Institute (OHRI) has been awarded a $300,000 USD G-Rex Grant.

  5. Signing Of An Agreement To Establish A Joint Venture For The Manufacture Of Biosimilars 11/25/2025

    Alfresa Holdings Corporation (head office: Chiyoda-ku, Tokyo; Representative Director & President: Ryuji Arakawa; hereinafter “Alfresa Holdings”); Kidswell Bio Corporation (head office: Chuo-ku, Tokyo; President & CEO: Shinya Kurebayashi; hereinafter “Kidswell”); Chiome Bioscience Inc. (head office: Shibuya-ku, Tokyo; President & CEO: Masamichi Koike; hereinafter “Chiome”), and Mycenax Biotech Inc. (head office: Hsinchu, Taiwan; CEO and President : Pei-Jiun Chen; hereinafter “Mycenax”) have now concluded an agreement to establish a joint venture for the manufacture of active pharmaceutical ingredients (APIs) and drug products for biosimilars (hereinafter “Biosimilars”)*1, following the basic agreement*2 the four companies reached on October 6 2025.

  6. Caring Cross And Amrita Research Center Delhi, Amrita Vishwa Vidyapeetham Announce Strategic Partnership To Advance Affordable Cell and Gene Therapies For Underserved Populations Across India 11/25/2025

    Caring Cross, a U.S.-based non-profit dedicated to expanding global access to advanced therapies, today announced a new partnership with the Amrita Research Center Delhi (ARCD) and Amrita Vishwa Vidyapeetham, a leading multi-campus, research-intensive university in India.

  7. medac CDMO Supports Urogen Pharma's Advancement Of UGN-103 11/24/2025

    This collaboration reflects a commitment to advancing meaningful therapies and ensuring patients worldwide gain access to effective, reliable treatment options.

  8. ToolGen And GenEditBio Enter Strategic Cross-License Agreement To Accelerate Development Of Innovative Genome-Editing Therapeutics 11/24/2025

    ToolGen Inc. (KOSDAQ: 199800), a leading genome editing company based in Korea, announced today that it has entered into a strategic cross-license agreement with GenEditBio Limited ("GenEditBio"), a Hong Kong-headquartered clinical-stage biotechnology company specializing in novel deliveries, including lipid nanoparticle (LNP)-based delivery systems.

  9. Made Scientific And Cellergy Therapeutics Announce Manufacturing Partnership To Advance First-In-Human Mitochondrial Therapy 11/24/2025

    Made Scientific, Inc., a leading U.S.-based clinical- and commercial-stage cell therapy contract development and manufacturing organization (CDMO), and Cellergy Therapeutics Ltd., a biotechnology company pioneering first-in-class mitochondrial transplantation therapies, today announced a manufacturing partnership to advance Cellergy's mitochondrial therapy CLG-001 toward first-in-human clinical studies.

  10. Microsize And Schedio Group To Acquire Lonza's Micro-Macinazione Site In Switzerland 11/24/2025

    Microsize, a leading CDMO specializing in particle size reduction and control technologies, today announced it has signed an agreement to acquire Micro-Macinazione (Mic Mac), a dedicated micronization facility in Monteggio, Switzerland, from Lonza.